# An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

> **NCT07720284** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 915 (estimated)

## Conditions studied

- High-risk Muscle Invasive Urothelial Carcinoma

## Interventions

- **DRUG:** Dato-DXd
- **DRUG:** Rilvegostomig
- **DRUG:** Durvalumab
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Enfortumab vedotin

## Key facts

- **NCT ID:** NCT07720284
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-16
- **Primary completion:** 2030-09-11
- **Final completion:** 2032-11-23
- **Target enrollment:** 915 (ESTIMATED)
- **Last updated:** 2026-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720284, "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*